- Report
- July 2024
- 100 Pages
Global
From €3447EUR$3,750USD£2,938GBP
- Report
- July 2024
- 150 Pages
Global
From €3447EUR$3,750USD£2,938GBP
- Report
- July 2026
- 90 Pages
China
From €4366EUR$4,750USD£3,721GBP
- Report
- June 2025
- 400 Pages
Global
From €4549EUR$4,949USD£3,877GBP
- Report
- July 2023
- 180 Pages
Global
From €4549EUR$4,949USD£3,877GBP
- Report
- April 2025
- 198 Pages
Global
From €4592EUR$4,995USD£3,913GBP
- Report
- May 2024
- 100 Pages
Africa
From €1838EUR$2,000USD£1,567GBP
- Report
- April 2024
- 80 Pages
China
From €1379EUR$1,500USD£1,175GBP
- Report
- April 2024
- 80 Pages
France
From €1379EUR$1,500USD£1,175GBP
- Report
- April 2024
- 80 Pages
Germany
From €1379EUR$1,500USD£1,175GBP
- Report
- April 2024
- 80 Pages
India
From €1379EUR$1,500USD£1,175GBP
- Report
- April 2024
- 80 Pages
Saudi Arabia
From €1379EUR$1,500USD£1,175GBP
- Report
- April 2024
- 80 Pages
South Korea
From €1379EUR$1,500USD£1,175GBP
From €1379EUR$1,500USD£1,175GBP
- Report
- April 2024
- 80 Pages
United Kingdom
From €1379EUR$1,500USD£1,175GBP
- Report
- April 2024
- 80 Pages
United States
From €1379EUR$1,500USD£1,175GBP
- Report
- April 2024
- 100 Pages
Africa
From €1838EUR$2,000USD£1,567GBP
- Report
- April 2024
- 80 Pages
China
From €1379EUR$1,500USD£1,175GBP
- Report
- April 2024
- 80 Pages
France
From €1379EUR$1,500USD£1,175GBP
- Report
- April 2024
- 80 Pages
Germany
From €1379EUR$1,500USD£1,175GBP

The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more